Risperdal Fends Off Generic Competition
A judge on Tuesday upheld Janssen Pharmaceutical NV's Risperdal patent in the face of a challenge by Apotex Inc., leaving Janssen with three fewer competitors in total vying for the antipsychotic....To view the full article, register now.
Already a subscriber? Click here to view full article